Literature DB >> 27287723

The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations.

Katrina Meeth1, Jake Xiao Wang2, Goran Micevic1, William Damsky2, Marcus W Bosenberg3,4.   

Abstract

The remarkable success of immune therapies emphasizes the need for immune-competent cancer models. Elegant genetically engineered mouse models of a variety of cancers have been established, but their effective use is limited by cost and difficulties in rapidly generating experimental data. Some mouse cancer cell lines are transplantable to immunocompetent host mice and have been utilized extensively to study cancer immunology. Here, we describe the Yale University Mouse Melanoma (YUMM) lines, a comprehensive system of mouse melanoma cell lines that are syngeneic to C57BL/6, have well-defined human-relevant driver mutations, and are genomically stable. This will be a useful tool for the study of tumor immunology and genotype-specific cancer biology.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  YUMM; cancer immunology; cell lines; melanoma; mouse models

Mesh:

Substances:

Year:  2016        PMID: 27287723      PMCID: PMC5331933          DOI: 10.1111/pcmr.12498

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  19 in total

1.  Blocking Tumor Necrosis Factor α Enhances CD8 T-cell-Dependent Immunity in Experimental Melanoma.

Authors:  Florie Bertrand; Julia Rochotte; Céline Colacios; Anne Montfort; Anne-Françoise Tilkin-Mariamé; Christian Touriol; Philippe Rochaix; Isabelle Lajoie-Mazenc; Nathalie Andrieu-Abadie; Thierry Levade; Hervé Benoist; Bruno Ségui
Journal:  Cancer Res       Date:  2015-05-14       Impact factor: 12.701

Review 2.  Molecular mechanisms of drug resistance.

Authors:  D B Longley; P G Johnston
Journal:  J Pathol       Date:  2005-01       Impact factor: 7.996

3.  CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma.

Authors:  Roberto A Salas Fragomeni; Hye Won Chung; Yosef Landesman; William Senapedis; Jean-Richard Saint-Martin; Hensin Tsao; Keith T Flaherty; Sharon Shacham; Michael Kauffman; James C Cusack
Journal:  Mol Cancer Ther       Date:  2013-04-24       Impact factor: 6.261

4.  Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis.

Authors:  C Nogueira; K-H Kim; H Sung; K H T Paraiso; J-H Dannenberg; M Bosenberg; L Chin; M Kim
Journal:  Oncogene       Date:  2010-08-16       Impact factor: 9.867

5.  Mouse skin melanoma induced in two stage chemical carcinogenesis with 7,12-dimethylbenz[a]anthracene and croton oil.

Authors:  H Takizawa; S Sato; H Kitajima; S Konishi; K Iwata; Y Hayashi
Journal:  Carcinogenesis       Date:  1985-06       Impact factor: 4.944

6.  Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma.

Authors:  Jessica A Cintolo; Jashodeep Datta; Shuwen Xu; Meera Gupta; Rajasekharan Somasundaram; Brian J Czerniecki
Journal:  Melanoma Res       Date:  2016-02       Impact factor: 3.599

7.  Therapy-induced tumour secretomes promote resistance and tumour progression.

Authors:  Anna C Obenauf; Yilong Zou; Andrew L Ji; Sakari Vanharanta; Weiping Shu; Hubing Shi; Xiangju Kong; Marcus C Bosenberg; Thomas Wiesner; Neal Rosen; Roger S Lo; Joan Massagué
Journal:  Nature       Date:  2015-03-25       Impact factor: 49.962

8.  Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.

Authors:  David Dankort; David P Curley; Robert A Cartlidge; Betsy Nelson; Anthony N Karnezis; William E Damsky; Mingjian J You; Ronald A DePinho; Martin McMahon; Marcus Bosenberg
Journal:  Nat Genet       Date:  2009-03-12       Impact factor: 38.330

9.  Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses.

Authors:  Ping-Chih Ho; Jessica Dauz Bihuniak; Andrew N Macintyre; Matthew Staron; Xiaojing Liu; Robert Amezquita; Yao-Chen Tsui; Guoliang Cui; Goran Micevic; Jose C Perales; Steven H Kleinstein; E Dale Abel; Karl L Insogna; Stefan Feske; Jason W Locasale; Marcus W Bosenberg; Jeffrey C Rathmell; Susan M Kaech
Journal:  Cell       Date:  2015-08-27       Impact factor: 41.582

10.  sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance.

Authors:  Amanpreet Kaur; Marie R Webster; Katie Marchbank; Reeti Behera; Abibatou Ndoye; Curtis H Kugel; Vanessa M Dang; Jessica Appleton; Michael P O'Connell; Phil Cheng; Alexander A Valiga; Rachel Morissette; Nazli B McDonnell; Luigi Ferrucci; Andrew V Kossenkov; Katrina Meeth; Hsin-Yao Tang; Xiangfan Yin; William H Wood; Elin Lehrmann; Kevin G Becker; Keith T Flaherty; Dennie T Frederick; Jennifer A Wargo; Zachary A Cooper; Michael T Tetzlaff; Courtney Hudgens; Katherine M Aird; Rugang Zhang; Xiaowei Xu; Qin Liu; Edmund Bartlett; Giorgos Karakousis; Zeynep Eroglu; Roger S Lo; Matthew Chan; Alexander M Menzies; Georgina V Long; Douglas B Johnson; Jeffrey Sosman; Bastian Schilling; Dirk Schadendorf; David W Speicher; Marcus Bosenberg; Antoni Ribas; Ashani T Weeraratna
Journal:  Nature       Date:  2016-04-04       Impact factor: 49.962

View more
  93 in total

1.  AKT1E17K Activates Focal Adhesion Kinase and Promotes Melanoma Brain Metastasis.

Authors:  David A Kircher; Kirby A Trombetti; Mark R Silvis; Gennie L Parkman; Grant M Fischer; Stephanie N Angel; Christopher M Stehn; Sean C Strain; Allie H Grossmann; Keith L Duffy; Kenneth M Boucher; Martin McMahon; Michael A Davies; Michelle C Mendoza; Matthew W VanBrocklin; Sheri L Holmen
Journal:  Mol Cancer Res       Date:  2019-05-28       Impact factor: 5.852

2.  Patterns of immune-cell infiltration in murine models of melanoma: roles of antigen and tissue site in creating inflamed tumors.

Authors:  Katie M Leick; Joel Pinczewski; Ileana S Mauldin; Samuel J Young; Donna H Deacon; Amber N Woods; Marcus W Bosenberg; Victor H Engelhard; Craig L Slingluff
Journal:  Cancer Immunol Immunother       Date:  2019-05-27       Impact factor: 6.968

3.  Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control.

Authors:  Emilio Sanseviero; Erin M O'Brien; Jenna R Karras; Tamer B Shabaneh; Bulent Arman Aksoy; Wei Xu; Cathy Zheng; Xiangfan Yin; Xiaowei Xu; Giorgos C Karakousis; Ravi K Amaravadi; Brian Nam; Mary Jo Turk; Jeff Hammerbacher; Mark P Rubinstein; Lynn M Schuchter; Tara C Mitchell; Qin Liu; Erica L Stone
Journal:  Cancer Immunol Res       Date:  2019-06-25       Impact factor: 11.151

Review 4.  PSGL-1: A New Player in the Immune Checkpoint Landscape.

Authors:  Roberto Tinoco; Dennis C Otero; Amy A Takahashi; Linda M Bradley
Journal:  Trends Immunol       Date:  2017-03-02       Impact factor: 16.687

5.  Melanoma to Vitiligo: The Melanocyte in Biology & Medicine-Joint Montagna Symposium on the Biology of Skin/PanAmerican Society for Pigment Cell Research Annual Meeting.

Authors:  Sancy A Leachman; Thomas J Hornyak; Greg Barsh; Boris C Bastian; Douglas E Brash; James E Cleaver; Cynthia D Cooper; John A D'Orazio; Mayumi Fujita; Sheri L Holmen; Arup K Indra; Kenneth H Kraemer; I Caroline Le Poole; Roger S Lo; Amanda W Lund; Prashiela Manga; William J Pavan; Vijayasaradhi Setaluri; Clara E Stemwedel; Molly F Kulesz-Martin
Journal:  J Invest Dermatol       Date:  2019-07-23       Impact factor: 8.551

6.  Multimodal Multiplexed Immunoimaging with Nanostars to Detect Multiple Immunomarkers and Monitor Response to Immunotherapies.

Authors:  Yu-Chuan Ou; Xiaona Wen; Christopher A Johnson; Daniel Shae; Oscar D Ayala; Joseph A Webb; Eugene C Lin; Rossane C DeLapp; Kelli L Boyd; Ann Richmond; Anita Mahadevan-Jansen; Marjan Rafat; John T Wilson; Justin M Balko; Mohammed N Tantawy; Anna E Vilgelm; Rizia Bardhan
Journal:  ACS Nano       Date:  2020-01-02       Impact factor: 15.881

7.  Tumor-Targeted, Cytoplasmic Delivery of Large, Polar Molecules Using a pH-Low Insertion Peptide.

Authors:  Alexander A Svoronos; Raman Bahal; Mohan C Pereira; Francisco N Barrera; John C Deacon; Marcus Bosenberg; Daniel DiMaio; Peter M Glazer; Donald M Engelman
Journal:  Mol Pharm       Date:  2020-01-13       Impact factor: 4.939

8.  A Designer Cross-reactive DNA Immunotherapeutic Vaccine that Targets Multiple MAGE-A Family Members Simultaneously for Cancer Therapy.

Authors:  Elizabeth K Duperret; Shujing Liu; Megan Paik; Aspen Trautz; Regina Stoltz; Xiaoming Liu; Kan Ze; Alfredo Perales-Puchalt; Charles Reed; Jian Yan; Xiaowei Xu; David B Weiner
Journal:  Clin Cancer Res       Date:  2018-09-27       Impact factor: 12.531

9.  Inhibiting Notch1 enhances immunotherapy efficacy in melanoma by preventing Notch1 dependent immune suppressive properties.

Authors:  Hong Qiu; Patrick M Zmina; Alex Y Huang; David Askew; Barbara Bedogni
Journal:  Cancer Lett       Date:  2018-07-21       Impact factor: 8.679

10.  BET Inhibition Modifies Melanoma Infiltrating T Cells and Enhances Response to PD-L1 Blockade.

Authors:  Neda Nikbakht; Manoela Tiago; Dan A Erkes; Inna Chervoneva; Andrew E Aplin
Journal:  J Invest Dermatol       Date:  2019-01-28       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.